IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation

doi:10.17305/bjbms.2022.7279

HFCAS OpenIR

	IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
	Xu, Yipeng 1,2,3; Pachnikova, Gabriela 4,5,6,7; Wang, He ; Wu, Yaoyao 8; Przybilla, Dorothea 4,5,6,7; Schaefer, Reinhold 4,5,6,7; Chen, Zihao 9; Zhu, Shaoxing 1,2,3; Keilholz, Ulrich 4,5,6,7,10
	2022
发表期刊	BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
ISSN	1512-8601
通讯作者	Zhu, Shaoxing(zhusx@zjcc.org.cn) ; Keilholz, Ulrich(ulrich.keilholz@charite.de)
摘要	Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50, curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
关键词	IC50 docetaxel spheroids drug testing preclinical models prostate cancer 2D clinical models 3D clinical models cell culture
DOI	10.17305/bjbms.2022.7279
关键词[WOS]	PATIENT-DERIVED XENOGRAFTS ; MODELS ; CULTURES ; GROWTH
收录类别	SCI
语种	英语
资助项目	Natural Science Foundation of Zhejiang Province[LQ20H160007] ; ZAST International Medical Cooperation Programme
项目资助者	Natural Science Foundation of Zhejiang Province ; ZAST International Medical Cooperation Programme
WOS研究方向	Research & Experimental Medicine
WOS类目	Medicine, Research & Experimental
WOS记录号	WOS:000876747500002
出版者	ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO
引用统计	被引频次：4[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130133
专题	中国科学院合肥物质科学研究院
通讯作者	Zhu, Shaoxing; Keilholz, Ulrich
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Urol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Key Lab Zhejiang Prov Aptamers & Theranost, Hangzhou, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc, Hangzhou, Peoples R China 4.Charite, Ctr Comprehens Canc, Berlin, Germany 5.Free Univ Berlin, Berlin, Germany 6.Humboldt Univ, Berlin, Germany 7.Berlin Inst Hlth, Berlin, Germany 8.Zhejiang Chinese Med Univ, Clin 2, Med Coll, Hangzhou, Zhejiang, Peoples R China 9.Southern Med Univ, Dept Urol, Guangzhou, Peoples R China 10.German Canc Consortium DKTK, Heidelberg, Germany
推荐引用方式 GB/T 7714	Xu, Yipeng,Pachnikova, Gabriela,Wang, He,et al. IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation[J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES,2022,22.
APA	Xu, Yipeng.,Pachnikova, Gabriela.,Wang, He.,Wu, Yaoyao.,Przybilla, Dorothea.,...&Keilholz, Ulrich.(2022).IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES,22.
MLA	Xu, Yipeng,et al."IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation".BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES 22(2022).